{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T08:12:09Z","timestamp":1769587929213,"version":"3.49.0"},"reference-count":27,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T00:00:00Z","timestamp":1639958400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Hemodialysis International"],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>This study described control of parathyroid hormone (PTH), phosphorus, and corrected calcium in adults initiating calcimimetics in small dialysis organizations after the introduction of etelcalcetide.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This retrospective study using Visonex Clarity electronic health records between October 1, 2017, and December 31, 2019, identified adults \u2265\u200918\u2009years of age receiving in\u2010center hemodialysis as either a cinacalcet or etelcalcetide initiator based on their first calcimimetic use in 2018 (index date) with no prior calcimimetic use in the 3\u00a0months preindex date. Patients were stratified by PTH at index date and were followed for 15\u2009months. Subcohorts of patients who were persistent on a single calcimimetic for 15\u2009months and of patients who had their calcimimetic changed from cinacalcet to etelcalcetide were also analyzed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Findings<\/jats:title><jats:p>A total of 677 patients initiated cinacalcet and 711 initiated etelcalcetide. Mean PTH (pg\/ml), phosphorus, and corrected calcium (mg\/dl) at baseline were 864, 5.9, and 9.3 for cinacalcet and 804, 5.9, and 9.4 for etelcalcetide, respectively. During follow\u2010up, the proportion of initiators considered in\u2010target (monthly average PTH &lt;\u2009600) increased from 48% to 62% with cinacalcet and from 56% to 86% with etelcalcetide in the baseline PTH 600 to &lt;\u2009800 subgroup; increased from 30% to 64% with cinacalcet and 31% to 59% with etelcalcetide among those with baseline PTH 800 to\u2009&lt;\u20091000; and increased from 14% to 41% with cinacalcet and 12% to 58% with etelcalcetide among those with baseline PTH \u22651000. A similar pattern was observed for persistent users (n\u00a0=\u00a0646). For patients changed from cinacalcet to etelcalcetide (n\u00a0=\u00a0183), the proportion of patients considered in\u2010target increased from 22% in the month prior to the treatment change to 51% in Month 6 postchange.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>Patients initiating calcimimetics at lower baseline PTH had better biochemical control than patients starting at higher PTH. Patients changed from cinacalcet to etelcalcetide had improvements in PTH control postchange.<\/jats:p><\/jats:sec>","DOI":"10.1111\/hdi.12996","type":"journal-article","created":{"date-parts":[[2021,12,21]],"date-time":"2021-12-21T05:49:52Z","timestamp":1640065792000},"page":"243-254","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Calcimimetic use in US hemodialysis facilities in first 2\u2009years after the launch of etelcalcetide: A descriptive analysis of real\u2010world clinical practice and outcomes"],"prefix":"10.1111","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9648-9004","authenticated-orcid":false,"given":"John Mark","family":"Stephens","sequence":"first","affiliation":[{"name":"Prima Health Analytics  Weymouth Massachusetts USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen M.","family":"Fox","sequence":"additional","affiliation":[{"name":"Amgen, Inc.  Thousand Oaks California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pooja","family":"Desai","sequence":"additional","affiliation":[{"name":"Amgen, Inc.  Thousand Oaks California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunfa","family":"Cheng","sequence":"additional","affiliation":[{"name":"Amgen, Inc.  Austin Texas USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William G.","family":"Goodman","sequence":"additional","affiliation":[{"name":"Amgen, Inc.  Thousand Oaks California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica B.","family":"Kendrick","sequence":"additional","affiliation":[{"name":"University of Colorado  Aurora Colorado USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,12,20]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2007.13.5.397"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10157-020-01879-8"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-020-02088-x"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfaa195"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.12941213"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.15081218"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2018.03.027"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.kisu.2017.04.001"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2017.07.019"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.04350420"},{"issue":"07","key":"e_1_2_6_12_1","first-page":"20","article-title":"Consider a step therapy approach for the treatment of hyperparathyroidism and mineral and bone disorder in patients on dialysis","volume":"33","author":"Aronoff GR","year":"2019","journal-title":"Nephrol News Issues"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1159\/000353298"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.34067\/KID.0003042020"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1159\/000510360"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfh1049"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.5812\/numonthly.9449"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfaa005"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1159\/000496562"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1186\/s41100-020-00310-y"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfz021"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2019.04.010"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11255-019-02217-y"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00268-019-05020-z"},{"key":"e_1_2_6_25_1","unstructured":"Federal Register Vol. 85 No. 217 FR\u20102020\u201011\u201009. 2020. Office of the Federal Register National Archives and Records Administration.https:\/\/www.govinfo.gov\/content\/pkg\/FR-2020-11-09\/pdf\/FR-2020-11-09.pdf"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2018.11.007"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.09580911"},{"issue":"5","key":"e_1_2_6_28_1","first-page":"28","article-title":"Amgen highlights dosing requirements for cinacalcet","volume":"36","author":"Goodman W","year":"2021","journal-title":"Nephrol News Issues"}],"container-title":["Hemodialysis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hdi.12996","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/hdi.12996","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hdi.12996","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T12:15:52Z","timestamp":1692965752000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hdi.12996"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,20]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["10.1111\/hdi.12996"],"URL":"https:\/\/doi.org\/10.1111\/hdi.12996","archive":["Portico"],"relation":{},"ISSN":["1492-7535","1542-4758"],"issn-type":[{"value":"1492-7535","type":"print"},{"value":"1542-4758","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,20]]},"assertion":[{"value":"2021-08-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-09","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}